Marcel Palamar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcel Palamar has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alexandru Sircuta
Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, Romania
5 shared publications - Flaviu Bob
Division of Nephrology, Department of Internal Medicine II, “Victor Babes” University of Medicine and Pharmacy, No. 2, Eftimie Murgu Sq., 300041 Timisoara, Romania
5 shared publications - Iulia Grosu
Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, Romania
5 shared publications - Adalbert Schiller
Centre for Molecular Research in Nephrology and Vascular Disease/MOL-NEPHRO-VASC, “Victor Babes” University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania
4 shared publications - Ligia Petrica
Centre for Cognitive Research in Neuropsychiatric Pathology (NeuroPsy-Cog), Department of Neurosciences, Victor Babes University of Medicine and Pharmacy, 156 L. Rebreanu Ave., 300736 Timisoara, Romania
4 shared publications - Maria Daniela Tanasescu
Nephrology Department, Bucharest Emergency University Hospital, 050098 Bucharest, Romania
3 shared publications
Latest Publications
- Open Access
Vascular Calcification in Chronic Kidney Disease and Hemodialysis: Pathophysiological Mechanisms and Emerging Biomarkers
Background and Objectives: Vascular calcification (VC) is a major contributor to cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD), particularly those on hemodialysis. Once considered a passive process, VC is now recognized as an active, cell-mediated pathology influenced by mineral dysregulation, chronic inflammation, and oxidative stress. This review aims to synthesize current evidence on the underlying mechanisms of VC in CKD and hemodialysis, with particular focus on emerging biomarkers and therapeutic implications. Materials and Methods: A structured narrative review was conducted by searching PubMed, Web of Science, ScienceDirect, and Google Scholar. The final search was completed on 29 August 2025. A total of 1326 articles were initially retrieved, of which 65 met the inclusion criteria and were analyzed. Studies addressing VC mechanisms, the bone–vascular axis, mineral metabolism, vitamin K–dependent proteins, and biomarkers such as matrix Gla protein (MGP), osteocalcin (OC), and intact parathyroid hormone (iPTH) were included. Results: VC in CKD arises from phenotypic transformation of vascular smooth muscle cells, vesicle-mediated calcification, oxidative stress, and impaired activity of endogenous calcification inhibitors. Disruption of the fibroblast growth factor 23 (FGF23)–Klotho axis and secondary hyperparathyroidism further exacerbate vascular pathology. Among emerging biomarkers, dp-ucMGP reflects vitamin K deficiency and correlates with calcification burden, while OC and iPTH provide insight into bone–vascular crosstalk and mineral turnover. However, biomarker interpretation is limited by assay variability, renal clearance, and clinical heterogeneity. Conclusions: VC in CKD represents a complex process driven by systemic and cellular dysregulation. While biomarkers such as dp-ucMGP, OC, and iPTH offer mechanistic insights and prognostic potential, further validation is required for clinical application. A multimarker approach, combined with individualized management of mineral metabolism, may improve risk stratification and therapeutic targeting in this high-risk population.
Open AccessVascular Calcification in Chronic Kidney Disease and Hemodialysis: Pathophysiological Mechanisms and Emerging Biomarkers
Background and Objectives: Vascular calcification (VC) is a major contributor to cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD), particularly those on hemodialysis. Once considered a passive process, VC is now recognized as an active, cell-mediated pathology influenced by mineral dysregulation, chronic inflammation, and oxidative stress. This review aims to synthesize current evidence on the underlying mechanisms of VC in CKD and hemodialysis, with particular focus on emerging biomarkers and therapeutic implications. Materials and Methods: A structured narrative review was conducted by searching PubMed, Web of Science, ScienceDirect, and Google Scholar. The final search was completed on 29 August 2025. A total of 1326 articles were initially retrieved, of which 65 met the inclusion criteria and were analyzed. Studies addressing VC mechanisms, the bone–vascular axis, mineral metabolism, vitamin K–dependent proteins, and biomarkers such as matrix Gla protein (MGP), osteocalcin (OC), and intact parathyroid hormone (iPTH) were included. Results: VC in CKD arises from phenotypic transformation of vascular smooth muscle cells, vesicle-mediated calcification, oxidative stress, and impaired activity of endogenous calcification inhibitors. Disruption of the fibroblast growth factor 23 (FGF23)–Klotho axis and secondary hyperparathyroidism further exacerbate vascular pathology. Among emerging biomarkers, dp-ucMGP reflects vitamin K deficiency and correlates with calcification burden, while OC and iPTH provide insight into bone–vascular crosstalk and mineral turnover. However, biomarker interpretation is limited by assay variability, renal clearance, and clinical heterogeneity. Conclusions: VC in CKD represents a complex process driven by systemic and cellular dysregulation. While biomarkers such as dp-ucMGP, OC, and iPTH offer mechanistic insights and prognostic potential, further validation is required for clinical application. A multimarker approach, combined with individualized management of mineral metabolism, may improve risk stratification and therapeutic targeting in this high-risk population.
- Open Access
IL-6 Versus TNF-α as Predictors of Echocardiographic Cardiac Remodeling in Maintenance Hemodialysis Patients
Background and Objectives: Cardiovascular disease remains the leading cause of mortality in end-stage renal disease, with systemic inflammation implicated in myocardial remodeling. We aimed to assess the associations between IL-6, TNF-α, and IL-1β and echocardiographic parameters of cardiac remodeling, including left ventricular mass (LVM), global longitudinal strain (GLS), interventricular septum (IVS), left ventricular end-diastolic diameter (LVEDD), and right ventricular diameter (RVD), in patients undergoing maintenance hemodialysis. This was a single-center retrospective observational study. Materials and Methods: In 58 maintenance hemodialysis patients (mean age 60.4 ± 11.7 years; 55% male), pre-dialysis serum cytokines (IL-6, TNF-α, IL-1β) and standard laboratory markers (C-reactive protein [CRP], albumin, hemoglobin) were measured. Echocardiography was performed under clinically stable conditions. Spearman correlations assessed relationships between cytokines and imaging parameters; multivariate linear regression identified independent predictors. Results: Median IL-6 was 7.36 pg/mL (interquartile range [IQR] 4.52–11.03), and median TNF-α was 9.35 pg/mL (IQR 7.9–12.57). IL-6 correlated positively with LVM (ρ = 0.63, p < 0.001), RVD (ρ = 0.53, p < 0.001), and CRP (ρ = 0.52, p < 0.001). In contrast, TNF-α inversely correlated with LVM (ρ = −0.36, p = 0.006). Multivariate regression showed IL-6 was independently predicted by LVM (p = 0.019) and RVD (p = 0.042), while TNF-α was predicted by age (p < 0.001), CRP (p = 0.038), and albumin (p = 0.012). Conclusions: In hemodialysis patients, IL-6 showed stronger associations with echocardiographic hypertrophy and dilation than TNF-α, supporting its role as a potential biomarker of subclinical cardiac remodeling.IL-6 showed stronger correlations with echocardiographic remodeling markers compared with TNF-α and may warrant further investigation as a potential biomarker in this setting.
Open AccessIL-6 Versus TNF-α as Predictors of Echocardiographic Cardiac Remodeling in Maintenance Hemodialysis Patients
Background and Objectives: Cardiovascular disease remains the leading cause of mortality in end-stage renal disease, with systemic inflammation implicated in myocardial remodeling. We aimed to assess the associations between IL-6, TNF-α, and IL-1β and echocardiographic parameters of cardiac remodeling, including left ventricular mass (LVM), global longitudinal strain (GLS), interventricular septum (IVS), left ventricular end-diastolic diameter (LVEDD), and right ventricular diameter (RVD), in patients undergoing maintenance hemodialysis. This was a single-center retrospective observational study. Materials and Methods: In 58 maintenance hemodialysis patients (mean age 60.4 ± 11.7 years; 55% male), pre-dialysis serum cytokines (IL-6, TNF-α, IL-1β) and standard laboratory markers (C-reactive protein [CRP], albumin, hemoglobin) were measured. Echocardiography was performed under clinically stable conditions. Spearman correlations assessed relationships between cytokines and imaging parameters; multivariate linear regression identified independent predictors. Results: Median IL-6 was 7.36 pg/mL (interquartile range [IQR] 4.52–11.03), and median TNF-α was 9.35 pg/mL (IQR 7.9–12.57). IL-6 correlated positively with LVM (ρ = 0.63, p < 0.001), RVD (ρ = 0.53, p < 0.001), and CRP (ρ = 0.52, p < 0.001). In contrast, TNF-α inversely correlated with LVM (ρ = −0.36, p = 0.006). Multivariate regression showed IL-6 was independently predicted by LVM (p = 0.019) and RVD (p = 0.042), while TNF-α was predicted by age (p < 0.001), CRP (p = 0.038), and albumin (p = 0.012). Conclusions: In hemodialysis patients, IL-6 showed stronger associations with echocardiographic hypertrophy and dilation than TNF-α, supporting its role as a potential biomarker of subclinical cardiac remodeling.IL-6 showed stronger correlations with echocardiographic remodeling markers compared with TNF-α and may warrant further investigation as a potential biomarker in this setting.
- Open Access
- 2 September 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (17) , 9654
Elevated Parathyroid Hormone Levels Are Associated with Increased Risk of Arteriovenous Fistula Thrombosis in Hemodialysis Patients: Findings from a 5-Year Cohort Study
(1) Background: Arteriovenous fistula (AVF) thrombosis represents a major cause of vascular access failure in patients undergoing maintenance hemodialysis. Identifying early biochemical markers associated with thrombosis may facilitate timely intervention and improve vascular outcomes. This study aimed to evaluate the association between baseline biochemical markers and the risk of AVF thrombosis and mortality during long-term follow-up. (2) Methods: We conducted a prospective observational study involving 249 chronic hemodialysis patients with functional AVFs. Baseline data included intact parathyroid hormone (iPTH), hemoglobin, phosphate, potassium, albumin, dialysis adequacy (Kt/V), age, diabetes status, and antivitamin K (AVK) therapy. Patients were followed for five years for the occurrence of AVF thrombosis and mortality. Statistical analysis was performed using one-way ANOVA with Levene’s test and Scheffé post hoc comparisons. (3) Results: iPTH levels were significantly higher in patients who developed AVF thrombosis (mean 494.6 pg/mL) than in those without thrombosis (mean 381.5 pg/mL; p = 0.047). Other variables, including hemoglobin, phosphate, Kt/V, age, diabetes, and AVK therapy, were not significantly associated with thrombosis. Mortality was more frequent among patients with diabetes mellitus and those receiving antivitamin K therapy; however, only the association with diabetes reached statistical significance. (4) Conclusions: Elevated iPTH was associated with AVF thrombosis. Routine monitoring may help identify high-risk patients and guide timely interventions.
- 2 September 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (17) , 9654
Open AccessElevated Parathyroid Hormone Levels Are Associated with Increased Risk of Arteriovenous Fistula Thrombosis in Hemodialysis Patients: Findings from a 5-Year Cohort Study
(1) Background: Arteriovenous fistula (AVF) thrombosis represents a major cause of vascular access failure in patients undergoing maintenance hemodialysis. Identifying early biochemical markers associated with thrombosis may facilitate timely intervention and improve vascular outcomes. This study aimed to evaluate the association between baseline biochemical markers and the risk of AVF thrombosis and mortality during long-term follow-up. (2) Methods: We conducted a prospective observational study involving 249 chronic hemodialysis patients with functional AVFs. Baseline data included intact parathyroid hormone (iPTH), hemoglobin, phosphate, potassium, albumin, dialysis adequacy (Kt/V), age, diabetes status, and antivitamin K (AVK) therapy. Patients were followed for five years for the occurrence of AVF thrombosis and mortality. Statistical analysis was performed using one-way ANOVA with Levene’s test and Scheffé post hoc comparisons. (3) Results: iPTH levels were significantly higher in patients who developed AVF thrombosis (mean 494.6 pg/mL) than in those without thrombosis (mean 381.5 pg/mL; p = 0.047). Other variables, including hemoglobin, phosphate, Kt/V, age, diabetes, and AVK therapy, were not significantly associated with thrombosis. Mortality was more frequent among patients with diabetes mellitus and those receiving antivitamin K therapy; however, only the association with diabetes reached statistical significance. (4) Conclusions: Elevated iPTH was associated with AVF thrombosis. Routine monitoring may help identify high-risk patients and guide timely interventions.
- Open Access
- 10 May 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1163
Associations Between Inflammatory and Bone Turnover Markers and Mortality in Hemodialysis Patients
Background/Objectives: Chronic kidney disease–mineral and bone disorder (CKD-MBD) and systemic inflammation contribute to mortality in hemodialysis (HD) patients. The primary aim of this study was to determine whether specific CKD-MBD markers and inflammatory biomarkers are associated with increased mortality risk in HD patients. Methods: We conducted a retrospective cohort study on 63 stage 5D CKD patients undergoing maintenance HD. Serum intact parathyroid hormone (iPTH), soluble Klotho, calcium, phosphorus, 25(OH)D (25-hydroxyvitamin D), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), C-reactive protein (CRP), and interleukin-6 (IL-6) were analyzed. A Cox regression analysis assessed mortality predictors, and linear regression analysis evaluated CKD-MBD–inflammation correlations. Results: Lower iPTH (p = 0.042). Other CKD-MBD markers (calcium, phosphorus, 25(OH)D, VEGF, TGF-β) did not impact survival. Soluble Klotho correlated positively with IL-6 (r = 0.57, p < 0.001), suggesting a compensatory inflammatory response. Conclusions: Our findings demonstrate that low iPTH levels and advanced age are independent predictors of mortality in hemodialysis patients. The positive association between soluble Klotho and IL-6 suggests a potential compensatory inflammatory response. These results highlight the need for further research to clarify underlying mechanisms and to explore novel therapeutic strategies.
- 10 May 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1163
Open AccessAssociations Between Inflammatory and Bone Turnover Markers and Mortality in Hemodialysis Patients
Background/Objectives: Chronic kidney disease–mineral and bone disorder (CKD-MBD) and systemic inflammation contribute to mortality in hemodialysis (HD) patients. The primary aim of this study was to determine whether specific CKD-MBD markers and inflammatory biomarkers are associated with increased mortality risk in HD patients. Methods: We conducted a retrospective cohort study on 63 stage 5D CKD patients undergoing maintenance HD. Serum intact parathyroid hormone (iPTH), soluble Klotho, calcium, phosphorus, 25(OH)D (25-hydroxyvitamin D), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), C-reactive protein (CRP), and interleukin-6 (IL-6) were analyzed. A Cox regression analysis assessed mortality predictors, and linear regression analysis evaluated CKD-MBD–inflammation correlations. Results: Lower iPTH (p = 0.042). Other CKD-MBD markers (calcium, phosphorus, 25(OH)D, VEGF, TGF-β) did not impact survival. Soluble Klotho correlated positively with IL-6 (r = 0.57, p < 0.001), suggesting a compensatory inflammatory response. Conclusions: Our findings demonstrate that low iPTH levels and advanced age are independent predictors of mortality in hemodialysis patients. The positive association between soluble Klotho and IL-6 suggests a potential compensatory inflammatory response. These results highlight the need for further research to clarify underlying mechanisms and to explore novel therapeutic strategies.
- Open Access
- 3 October 2023
- Published by MDPI AG in Applied Sciences
- Vol. 13 (19) , 10938
Vitamin K Status of Patients Undergoing Hemodialysis: Insights from a Cross-Sectional Study
(1) Background: Vitamin K deficiency is a common feature of chronic kidney disease (CKD), leading to impaired bone quality and an increased risk of vascular calcifications. A method to indirectly assess the vitamin K status is measuring the blood level of vitamin K-dependent proteins (VKDP): osteocalcin (OC) and matrix GLA protein (MGP). The aim of this study is to correlate the level of total OC and inactive MGP (dp-uc MGP) with markers of CKD mineral bone disorder (CKD-MBD). (2) Methods: We conducted a single-center cross-sectional study that included 45 CKD G5D patients and measured their blood biochemistry, complete blood count and total osteocalcin and dp-uc MGP contents. (3) Results: We found a strong, statistically significant correlation of the total OC with the markers of CKD-MBD, such as: iPTH, serum calcium and serum phosphorus, and a strong, indirect statistically significant correlation with abdominal circumference. There was also a statistically significant correlation of dp-uc MGP with the markers of inflammation (CRP). Higher levels of dp-uc MGP were found in the patients treated with vitamin K antagonists, non-calcium-based phosphate binders and the vitamin D receptor activator, paricalcitol. (4) Conclusions: In our study, we found that when it is measured indirectly using VKDP levels, vitamin K deficiency is associated with CKD-MBD. Certain widely used medications such as phosphate binders reduce vitamin K absorption, supplementary vitamin D increases vitamin K requirements, and also vitamin K antagonists influence the blood level of VKDPs.
- 3 October 2023
- Published by MDPI AG in Applied Sciences
- Vol. 13 (19) , 10938
Open AccessVitamin K Status of Patients Undergoing Hemodialysis: Insights from a Cross-Sectional Study
(1) Background: Vitamin K deficiency is a common feature of chronic kidney disease (CKD), leading to impaired bone quality and an increased risk of vascular calcifications. A method to indirectly assess the vitamin K status is measuring the blood level of vitamin K-dependent proteins (VKDP): osteocalcin (OC) and matrix GLA protein (MGP). The aim of this study is to correlate the level of total OC and inactive MGP (dp-uc MGP) with markers of CKD mineral bone disorder (CKD-MBD). (2) Methods: We conducted a single-center cross-sectional study that included 45 CKD G5D patients and measured their blood biochemistry, complete blood count and total osteocalcin and dp-uc MGP contents. (3) Results: We found a strong, statistically significant correlation of the total OC with the markers of CKD-MBD, such as: iPTH, serum calcium and serum phosphorus, and a strong, indirect statistically significant correlation with abdominal circumference. There was also a statistically significant correlation of dp-uc MGP with the markers of inflammation (CRP). Higher levels of dp-uc MGP were found in the patients treated with vitamin K antagonists, non-calcium-based phosphate binders and the vitamin D receptor activator, paricalcitol. (4) Conclusions: In our study, we found that when it is measured indirectly using VKDP levels, vitamin K deficiency is associated with CKD-MBD. Certain widely used medications such as phosphate binders reduce vitamin K absorption, supplementary vitamin D increases vitamin K requirements, and also vitamin K antagonists influence the blood level of VKDPs.